Crossref
PRECLINICAL EVALUATION OF HER2-DIRECTED CAR T-CELL THERAPY IN HER2-POSITIVE CHOLANGIOCARCINOMA
HPB · 2026 · 28 · S24
DOI: 10.1016/j.hpb.2026.04.040 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2026. Verfasst von Maen Abdelrahim und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Abdelrahim, M., Jiang, Z., Esmail, A., Zhu, Y., Peng, Z., Xing, H., Fang, J., Su, P., & Yong, L. (2026). PRECLINICAL EVALUATION OF HER2-DIRECTED CAR T-CELL THERAPY IN HER2-POSITIVE CHOLANGIOCARCINOMA. HPB, 28, S24. https://doi.org/10.1016/j.hpb.2026.04.040
Vancouver
Abdelrahim M, Jiang Z, Esmail A, Zhu Y, Peng Z, Xing H, et al. PRECLINICAL EVALUATION OF HER2-DIRECTED CAR T-CELL THERAPY IN HER2-POSITIVE CHOLANGIOCARCINOMA. HPB. 2026;28:S24. doi:10.1016/j.hpb.2026.04.040
BibTeX
@article{Abdelrahim2026,
author = {Abdelrahim, Maen and Jiang, Zhiwu and Esmail, Abdullah and Zhu, Yiran and Peng, Ziyi and Xing, Hui and Fang, Jing and Su, Pan and Yong, Lu},
title = {PRECLINICAL EVALUATION OF HER2-DIRECTED CAR T-CELL THERAPY IN HER2-POSITIVE CHOLANGIOCARCINOMA},
journal = {HPB},
year = {2026},
volume = {28},
pages = {S24},
doi = {10.1016/j.hpb.2026.04.040}
}
EUVIMED